Mortality benefit was nominally significant with dapagliflozin but not with empagliflozin or sotagliflozin, raising questions regarding differences in baseline risk profiles or play of chance.
← all excerpts
Robustness of outcomes in trials evaluating sodium-glucose co-transporter 2 inhibitors for heart failure.
1
—
—